Aripiprazole for Tourette's syndrome: a systematic review and meta‐analysis

  title={Aripiprazole for Tourette's syndrome: a systematic review and meta‐analysis},
  author={Wei Zheng and Xian-Bin Li and Ying-qiang Xiang and Bao-Liang Zhong and Helen Fung Kum Chiu and Gabor S. Ungvari and Chee H. Ng and Grace K I Lok and Yutao Xiang},
  journal={Human Psychopharmacology: Clinical and Experimental},
  pages={11 - 18}
  • W. Zheng, Xian-Bin Li, Y. Xiang
  • Published 1 January 2016
  • Psychology, Medicine
  • Human Psychopharmacology: Clinical and Experimental
To review the efficacy and safety of aripiprazole (ARI) for Tourette's syndrome (TS). 

Tics in the Pediatric Population: Pragmatic Management

Primary tic disorders, notably Tourette syndrome, are very common movement disorders in childhood. However, the management of such patients still poses great therapeutic challenges to medical

Immunity and Gilles de la Tourette syndrome: A systematic review and meta‐analysis of evidence for immune implications in Tourette syndrome

A systematic review and meta‐analysis of evidence for immune‐related events following possible environmental inducers of Gilles de la Tourette syndrome looked for evidence in favor of such possibilities.

Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders

The combined results from randomized controlled trials and open-label studies showed that aripiprazole is an effective, safe, and well-tolerated medication for the treatment of tics.


The case of a pediatric patient with TS who was admitted to the hospital after demonstrating severe involuntary movements and was selected Aripiprazole because of its unique mechanism of action resulted in a dopamine stabilizer feature with less side effect.

A Review of Differences in Clinical Characteristics between Tardive Syndrome Induced or Improved by Aripiprazole Treatment.

It is important for clinicians to pay attention to the risk of tardive syndrome when prescribing aripiprazole in patients with a diagnosis other than a psychiatric illness or in the long-term administration of aripIPrazole.

European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: pharmacological treatment

Overall, treatment of TS should be individualized, and decisions based on the patient’s needs and preferences, presence of co-existing conditions, latest scientific findings as well as on the physician's preferences, experience, and local regulatory requirements are presented.

Recent Advances in Understanding and Managing Tourette Syndrome

This review will highlight recent developments in the understanding and management strategies of Tourette syndrome, a neurologic and behavioral disorder consisting of motor and phonic tics with onset in childhood or adolescence.

Tics and Tourette’s syndrome

  • S. Mittal
  • Medicine, Psychology
    Drugs in context
  • 2020
The treatment ranges from behavioral therapies, medical management, and also surgical treatment such as deep brain stimulation that is limited to refractory patients.

Current pharmacotherapy for tic disorders

This literature review encompasses pharmacotherapies for tics, which include alpha agonists, antipsychotics, topiramate, botulinum toxin, and dopamine depleters.



A case series of patients with Tourette's syndrome in the United Kingdom treated with aripiprazole

These cases illustrate that a new neuroleptic, aripiprazole, may be an effective treatment for the motor and vocal tics of Tourette Syndrome (TS), even in younger people.

Topiramate for Tourette's syndrome in children: a meta-analysis.

Systemic review of aripiprazole for the treatment of children and adolescents with tic disorders.

Current evidence suggests that aripiprazole is effective for treating tic and Tourette disorders in both children and adolescents, and it seems that its adverse effect profile is safer than pimozide and some other antipsychotics.

Case series on the use of aripiprazole for Tourette syndrome.

A retrospective chart review of six youth with TS and comorbid obsessive–compulsive disorder (OCD) who were treated for 12 wk with aripiprazole shows value for treating neuropsychiatric disorders in children.

Treatment of Tourette's syndrome with haloperidol, review of 34 cases.

Most patients were able to achieve over 90% decrease in their symptoms after one year of treatment and Haloperidol was a difficult drug to use effectively.

A case of late-onset Tourette's disorder successfully treated with aripiprazole: View from blood levels of catecholamine metabolites and brain-derived neurotrophic factor (BDNF)

The present case suggests that aripiprazole might ameliorate tics and emotional instability via influencing dopaminergic neurons in late-onset TD.

Aripiprazole for the Treatment of Tourette Syndrome: A Case Series of 100 Patients

The results corroborate previous data suggesting that aripiprazole is effective and safe in most patients and clarify that beneficial effects sustain and confirm effectiveness in adult patients.

[A multicenter controlled study on aripiprazole treatment for children with Tourette syndrome in China].

Aripiprazole was safe and well tolerated in Chinese population, and can be considered as a new valid option for the treatment of tic disorders.

Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study.

Aripiprazole appears to be a safe and tolerable treatment in children and adolescents with TD that appears to reduce tics; it should be further investigated as a treatment option in controlled trials.

Acute Dystonia with Low-Dosage Aripiprazole in Tourette's Disorder

This is the first report concerning an aripiprazole-induced dystonic episode in an adult, and it is especially notable because it occurred at low dosage.